
Dr. Steve Harr discusses Sana Biotechnology's advancements in creating insulin-producing cells for Type I diabetics without immunosuppressants.
This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without the need for immunosuppressant drugs.
Explore listener stats, chart rankings, contacts and more on the BioTech Nation ... with Dr. Moira Gunn podcast page.